David Tabernero
Overview
Explore the profile of David Tabernero including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
550
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Palom A, Rando-Segura A, Fernandez G, Calatayud L, Selles-Sanchez A, Perez Del Campo D, et al.
BMJ Open
. 2024 Nov;
14(11):e086961.
PMID: 39581731
Introduction: Hepatitis B virus (HBV) affects 296 million people globally, causing 780 000 annual deaths. It has been estimated that 12-43 million individuals are co-infected with hepatitis D virus (HDV)....
2.
Gregori J, Colomer-Castell S, Ibanez-Lligona M, Garcia-Cehic D, Campos C, Buti M, et al.
Microorganisms
. 2024 May;
12(5).
PMID: 38792840
The repeated failure to treat patients chronically infected with hepatitis E (HEV) and C (HCV) viruses, despite the absence of resistance-associated substitutions (RAS), particularly in response to prolonged treatments with...
3.
Dopico E, Vila M, Tabernero D, Gregori J, Rando-Segura A, Pacin-Ruiz B, et al.
Int J Mol Sci
. 2024 May;
25(10).
PMID: 38791519
Our aim was to develop an accurate, highly sensitive method for HBV genotype determination and detection of genotype mixtures. We examined the preS and 5' end of the HBV X...
4.
Colomer-Castell S, Gregori J, Garcia-Cehic D, Riveiro-Barciela M, Buti M, Rando-Segura A, et al.
Int J Mol Sci
. 2023 Dec;
24(24).
PMID: 38139013
Here, we report the in-host hepatitis E virus (HEV) quasispecies evolution in a chronically infected patient who was treated with three different regimens of ribavirin (RBV) for nearly 6 years....
5.
Roade L, Riveiro-Barciela M, Pfefferkorn M, Sopena S, Palom A, Bes M, et al.
JHEP Rep
. 2023 Sep;
5(10):100842.
PMID: 37745192
Background & Aims: HBsAg proteins are useful to identify HBV inactive carriers (ICs), but data on chronic hepatitis D (CHD) are scarce. This study aimed to describe HBsAg composition in...
6.
Gregori J, Colomer-Castell S, Campos C, Ibanez-Lligona M, Garcia-Cehic D, Rando-Segura A, et al.
Int J Mol Sci
. 2022 Dec;
23(23).
PMID: 36498981
The changes occurring in viral quasispecies populations during infection have been monitored using diversity indices, nucleotide diversity, and several other indices to summarize the quasispecies structure in a single value....
7.
Roade L, Riveiro-Barciela M, Palom A, Rodriguez-Frias F, Bes M, Rando A, et al.
J Clin Transl Hepatol
. 2022 Nov;
10(6):1068-1076.
PMID: 36381089
Background And Aims: Hepatitis B virus (HBV) biomarkers have been used for a better categorization of patients, even though the lack of simple algorithms and the impact of genotypes limit...
8.
Garcia-Garcia S, Caballero-Garralda A, Tabernero D, Cortese M, Gregori J, Rodriguez-Algarra F, et al.
Biomedicines
. 2022 May;
10(5).
PMID: 35625929
Deletions in the 3' end region of the hepatitis B virus (HBV) X open reading frame () may affect the core promoter (Cp) and have been frequently associated with hepatocellular...
9.
Cortese M, Riveiro-Barciela M, Tabernero D, Rodriguez-Algarra F, Palom A, Sopena S, et al.
Microbiol Spectr
. 2022 Apr;
10(2):e0214921.
PMID: 35377229
The measurement and interpretation of HBV DNA and RNA levels in HBV infected patients treated with antiviral therapy supports the objective of HBV disease management. Here, we quantified circulating HBV...
10.
Quer J, Colomer-Castell S, Campos C, Andres C, Pinana M, Cortese M, et al.
Viruses
. 2022 Mar;
14(3).
PMID: 35337007
Virus pandemics have happened, are happening and will happen again. In recent decades, the rate of zoonotic viral spillover into humans has accelerated, mirroring the expansion of our global footprint...